SCHEMBL2179818

SCHEMBL2179818

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccc(F)c(F)c4)c(F)c3)cc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
THRB P10828 1/20 0.44
KDR P35968 1/20 0.41
SDCBP O00560 5/20 0.41
SDC2 P34741 5/20 0.41
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 1/20 0.40
CSGALNACT1 Q8TDX6 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
DGAT1 O75907 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719256 1.00 LMNA (0.44) LMNATHRBKDRSDCBPSDC2
SCHEMBL2176967 0.93 CSGALNACT1 (0.43) LMNATHRBKDRSDCBPSDC2
SCHEMBL2179349 0.93 CSGALNACT1 (0.43) LMNATHRBKDRSDCBPSDC2
SCHEMBL2179002 0.91 LMNA (0.49) LMNATHRBKDRSDCBPSDC2
SCHEMBL2178995 0.91 LMNA (0.49) LMNATHRBKDRSDCBPSDC2
SCHEMBL2178261 0.91 MAPT (0.43) LMNATHRBKDRSDCBPSDC2
SCHEMBL13719149 0.91 NPC1 (0.52) LMNATHRBKDRSDCBPSDC2
SCHEMBL2180144 0.91 NPC1 (0.52) LMNATHRBKDRSDCBPSDC2
SCHEMBL2178484 0.89 LMNA (0.51) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2178978 0.89 LMNA (0.51) LMNATHRBSDCBPSDC2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885THRB 2612/4885KDR 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.